Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| MediWound Limited | MDWD | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 17.66 | 04:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 17.66 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 7.10 - 18.75 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 17.66 | USD |
MediWound Limited Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 127.86M | 7.24M | - | 18.9M | -6.72M | -0.93 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
MediWound News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MDWD Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 16.95 | 18.25 | 15.25 | 16.71 | 60,278 | 0.71 | 4.19% |
| 1 Month | 14.04 | 18.75 | 13.5656 | 16.15 | 83,918 | 3.62 | 25.78% |
| 3 Months | 12.70 | 18.75 | 11.04 | 15.42 | 77,237 | 4.96 | 39.06% |
| 6 Months | 8.00 | 18.75 | 7.45 | 14.22 | 49,747 | 9.66 | 120.75% |
| 1 Year | 11.66 | 18.75 | 7.10 | 12.91 | 33,550 | 6.00 | 51.46% |
| 3 Years | 32.20 | 43.54 | 7.10 | 20.21 | 110,309 | -14.54 | -45.16% |
| 5 Years | 37.38 | 43.54 | 7.10 | 22.14 | 104,073 | -19.72 | -52.76% |
MediWound Description
| MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. Its first biopharmaceutical product, NexoBrid removes dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns also referred to as severe burns. NexoBrid is currently in clinical development in North America and is in the process of preparing its Biologics License Application. The company derives its revenue from the United States. |
